Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.2278
-0.0258 (-10.17%)
Oct 8, 2026, 12:45 PM EDT - Market open
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes Silexion Therapeutics the 39,281st largest employer in the world and 5,829th in the United States.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$997,000
Market Cap
1.27M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Virax Biolabs Group | 26 |
| Curis | 24 |
| Tessera Defense and Homeland Security | 20 |
| Decoy Therapeutics | 11 |
| Artelo Biosciences | 7 |
| CDT Equity | 4 |
| Oragenics | 3 |
| Bone Biologics | 2 |
SLXN News
- 8 days ago - Silexion announces first patient dosed in Phase 2/3 trial of SIL204 - TheFly
- 8 days ago - Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 9 days ago - Silexion Therapeutics Announces Exercise of Warrants - GlobeNewsWire
- 10 days ago - Silexion Therapeutics reports preclinical findings for SIL204 - TheFly
- 10 days ago - Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers - GlobeNewsWire
- 4 weeks ago - Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics prices $2.5M public offering at $0.65 per share - TheFly
- 7 weeks ago - Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire